(Renal Cell Carcinoma) Is Opdivo Monotherapy or Opdivo Plus Yervoy Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- May 16, 2022
- 1 min read
On April 20, 2022, Dr. Michael B. Atkins and colleagues from Georgetown Lombardi Comprehensive Cancer Center published results in the Journal of Clinical Oncology from the Phase 2 clinical trial (NCT03117309) evaluating the efficacy and safety of Opdivo (nivolumab) monotherapy and Opdivo plus Yervoy (ipilimumab) in treatment-naive patients with advanced clear cell renal cell carcinoma (ccRCC).
This Phase 2 trial enrolled 123 treatment-naive patients with advanced ccRCC. Patients first received Opdivo monotherapy (Part A, up to 96 weeks); those with disease progression or stable disease at 48 weeks switched to Opdivo plus Yervoy (Part B). The primary endpoint was 1-year progression-free survival (PFS) rate in patients with PD-L1 expression of 0% and ≥20%.
Results:
Overall ORR: 34.1%. ORR by IMDC risk category: favorable-risk 57.1%, intermediate-/poor-risk 25.0%, sarcomatoid features 36.4%.
ORR by PD-L1 expression: 0% PD-L1: 26.9%; 1–20% PD-L1: 50.0%; ≥20% PD-L1: 75.0%. Median duration of response: 27.6 months. Primary endpoint 1-year PFS: 0% PD-L1: 34.6%; ≥20% PD-L1: 75.0%.
In Part A, 96 patients experienced disease progression or stable disease, of whom 35 entered Part B. Part B ORR: 11.4%. Grade 3 or higher adverse events: Opdivo monotherapy 35%; Opdivo plus Yervoy 43%.
Conclusion: Based on the Phase 2 trial results, Dr. Atkins and colleagues concluded that Opdivo monotherapy demonstrated meaningful anti-tumor activity in treatment-naive advanced ccRCC patients, with activity correlated with PD-L1 expression. The combination of Opdivo plus Yervoy showed limited anti-tumor activity in this setting.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.02938
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4